Assessing the utility of submaximal cardiopulmonary exercise testing in diagnosis and treatment management of pulmonary arterial hypertension
Ended Project Grant Awarded Last action
- Award ID
- R44HL162169
- Recipient
-
Shape Medical Systems Inc. UEI NAWSENN3G5M7
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $591,129
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Place of performance
- Minnesota, USA
Award details come from USAspending.gov.
Description
- Abstract
- Pulmonary hypertension (PH) is a devastating disease characterized by progressive dyspnea/exercise intolerance, right-heart failure, and carries a high risk of morbidity and early mortality. PH disease progression can be rapid, and any delay in the diagnosis and treatment of PH likely reduces survival. Given its clinical and prognostic significance, early and accurate diagnosis of PH to allow prompt and optimal establishment of clinical care is of critical importance. While traditional maximal/comprehensive cardiopulmonary exercise testing (cpet) has been validated in PH, IT has limitations that have hindered its applicability to routine clinical assessment and monitoring. Our preliminary data suggest that the signature ventilatory and pulmonary gas exchange derangements of PH become apparent during even submaximal exercise. Our comprehensive proof-of-concept study (133 patients) supports our hypothesis that the addition of pulmonary gas exchange responses to a standardized 3-minute submaximal exercise test (shape icpet) to standard echocardiographic evidence of PH (i.e. rvsp >50 mmhg, suspicion of RV dysfunction) improves the sensitivity for PH detection by almost 40%. The shape icpet system is compact and utilizes pattern-recognition software that automates interpretation, making the system ideally suitable for widespread adoption. The overarching objective of this sbir proposal is to categorically establish the shape icpet as a tool that: 1) improves early detection of PH; and 2) provides an objective evidence-based measure of PH therapy efficacy that can be easily used in academic and community practices. We have established a 10-center consortium of academic and community PH centers for this sbir proposal. Specific aim 1 will assess the clinical utility of submaximal cardiopulmonary exercise testing as a complementary tool for the identification of pulmonary hypertension. Specific aim 2 will assess whether pharmacotherapy-induced improvements in pulmonary hypertension severity and disease status are reflected in the physiological responses to a standardized submaximal cardiopulmonary exercise test. We hypothesize that the shape icpet will prove to be an efficacious adjunct to traditional clinical metrics to track changes in pulmonary vascular function over time and responses to therapy aimed at alleviating PAH.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$844,522 | |
| Amendment | -$505,839 | |
| Amendment | -$1,350,361 | |
| Amendment | $844,522 | |
| Amendment | $1,223,664 | |
| Original award | $1,223,664 |
Quick answers
Who received award R44HL162169?
R44HL162169 was awarded to Shape Medical Systems Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 1, 2022.
How much is award R44HL162169 worth?
$591,129 has been obligated on R44HL162169.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award